Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

Summary

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.

Timeline

Start

2021-07-15

Primary completion

2023-04-04

Completion

2023-04-14

Drugs

Indications